Refine by
In Vitro Skin Models Articles & Analysis
17 news found
We are proud to introduce Myelotracker®, a peptide-based probe. This unique technology specifically targets lactoferrin, a major protein stored in neutrophil granules, making it possible to visualize and study these immune cells with unmatched precision. Unlike many existing tools, Myelotracker does not activate neutrophils, preserving their natural physiological state and ensuring reliable ...
BIOtechNOW featured IVS’s participating BIO Innovation Zone Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech ...
In the process of drug development, the evaluation of drug effectiveness is one of the keys to determining whether prodrugs can sufficiently reach the market stage. BOC Sciences, as a professional contract research organization, can take care of the PROTAC in vivo evaluation workload for clients with a transparent project process and comprehensive evaluation reports to facilitate their PROTAC ...
ArterioSorb has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model. Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the formation of thrombus. Shengjui, from Nicolas ...
MatTek Life Sciences will distribute Cell4Pharma’s ciPTEC renal cells and utilize the technology in the development of a new in vitro kidney model. MatTek Life Sciences, a Boston-area tissue engineering company and a member of the BICO Group, announced today it has entered into a distribution agreement and strategic partnership with Cell4Pharma, a ...
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has signed a Master Collaboration Agreement with the University of Miami to accelerate development of the Company's ImmCelz® ...
Study results demonstrate GBA1-targeted allosteric regulators increase GCase protein levels, reduce the production of inflammatory cytokines, and improve key lysosomal functions BETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric ...
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb utilizing Prellis Biologics’ first-in-class externalized human immune system (EXIS) based on human lymph node organoids (LNO). The collaboration leverages Prellis’ EXIS platform that ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. “The EXIS platform offers unprecedented in vitro ...
Through control of properties such as substrate mechanical stiffness and adhesion ligand presentation, materials can be designed that enable more physiologically relevant extracellular environments and better direct cellular behaviors within 3D models. At Stem Pharm, we are applying these principles to design PEG-based hydrogels for the development of in vitro neural models. ...
Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM Organ-On-a-Chip (OOC) range of Single- and Multi-Organ Microphysiological Systems (MPS) The companies share a common goal of developing and supplying advanced cell models that better reflect an in vivo environment to improve drug discovery accuracy ...
Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for the treatment of severe diarrhea induced by shiga-toxin (Stx) producing E. coli (STEC, leading to Hemolytic Uremic Syndrome), at the 14th Annual CRISPR 2021 meeting held June 1-10, 2021. The data presented further supports ...
HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced the publication of in vitro pharmacology data in the journal Molecular Genetics and Metabolism, demonstrating that the oral small molecule HST5040 may be effective in treating Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA). The company has initiated the HERO (HElp ...
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announces it has received a research grant of $440,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutic Pipeline Program. The award will enable development of a novel ...
Biofilm creation - among others - is one of the most important factors linked to infections and almost the only one that can be measured through simulation. T-Control demonstrated superiority vs gold standard, i.e. significant differences were observed between the biofilm quantity generated on the product´s surface. This result reinforces the hypothesis that T-Control, with it´s ...
Agilent Technologies Inc. (NYSE: A) today announced that Dr. Paul B. Watkins, international drug safety expert and director of the Hamner-University of North Carolina Institute for Drug Safety Sciences, has received an Agilent Thought Leader Award in recognition of his ongoing work developing integrated methods to predict drug-induced liver injury (DILI). This award continues Agilent's support ...